Praluent

Praluent

alirocumab

Manufacturer:

sanofi-aventis

Distributor:

DKSH
Concise Prescribing Info
Contents
Alirocumab
Indications/Uses
Adjunct to diet & maximally tolerated statin therapy in adults w/ heterozygous familial hypercholesterolemia or clinical atherosclerotic CV disease who require additional lowering of LDL-C.
Dosage/Direction for Use
75 mg SC once every 2 wk. Alternative starting dose: 300 mg once every 4 wk.
Contraindications
Special Precautions
Not to be inj into active skin disease areas or injury eg, sunburns, skin rashes, inflammation or infections. Discontinue use if serious allergic reactions occur. Severe renal & hepatic impairment. Not recommended during pregnancy & lactation. Childn & adolescents <18 yr.
Adverse Reactions
Local inj site reactions eg, erythema/redness, itching, swelling, pain/tenderness; upper resp tract signs & symptoms eg, oropharyngeal pain, rhinorrhea, sneezing; pruritus.
Drug Interactions
Increased target-mediated clearance & reduced systemic exposure w/ statins & other lipid-modifying therapy.
ATC Classification
C10AX14 - alirocumab ; Belongs to the class of other lipid modifying agents.
Presentation/Packing
Form
Praluent soln for inj 75 mg/mL
Packing/Price
1's;2's;6's
Form
Praluent soln for inj 150 mg/mL
Packing/Price
1's;2's;6's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in